SOPHiA GENETICS (SOPH) CEO Jurgi Camblong Sells $7.8K of Stock

Jurgi Camblong's Recent Sale

Jurgi Camblong, the Chief Executive Officer of SOPHiA GENETICS SA (NasdaqGS: SOPH), sold 1,373 shares on June 25, 2026. This transaction was valued at approximately $7,826.10, with the shares sold at an average price of $5.70 each. This sale is part of a planned transaction, reflecting Camblong's ongoing management of his holdings.

Insider Buying and Selling at SOPHiA GENETICS SA

This sale comes shortly after Camblong's notable purchase of 31,940 shares on June 26, 2026. This indicates a mixed pattern of trading activity, as he has recently shown both confidence in the company's prospects through buying and a willingness to sell shares. On the same day as Camblong's sale, Chief Technology Officer Abhimanyu Verma sold 6,944 shares, while Chief Medical Officer Philippe Menu sold 5,000 shares. These transactions highlight a broader trend of insider selling at SOPHiA GENETICS.

How SOPHiA GENETICS SA Stock Has Traded

Currently, SOPHiA GENETICS shares are trading at $5.98. This price is significantly lower than its 52-week high of $8.98. The stock's performance has been under pressure, especially after closing at $8.19 prior to the recent trades. Investors may be watching how the stock reacts to these insider sales and the overall market conditions.

Recent Earnings

In its latest earnings report, SOPHiA GENETICS reported revenue of approximately $86.2 million, with a revenue growth of 27.2%. However, the company has faced challenges with a net margin of -93.86% and an EPS of -$1.16. The next earnings report is scheduled for November 3, 2026, which may provide further insights into the company's financial health.

Analysts Set New Price Targets

Analysts have generally maintained a positive view of SOPHiA GENETICS. On October 12, 2026, HC Wainwright & Co. reiterated its "Buy" rating with a price target of $14.00. This follows an earlier update on August 5, 2026, where the firm maintained its rating but raised the target from $12.00 to $14.00. BTIG also maintains a "Buy" rating with a price target of $9.00.

What SOPHiA GENETICS SA Does

SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It specializes in cloud-native software solutions that help in analyzing complex data for healthcare providers and biopharmaceutical companies. The recent insider transactions, including Camblong's sales, may reflect strategic adjustments in response to market conditions.

What’s Next for SOPHiA GENETICS

Investors will be looking ahead to the next earnings date on November 3, 2026, for updates on the company's performance. It's important to note that the recent insider transactions reflect past activity and may not represent current positions. As the company navigates these challenges, further developments in insider trading and analyst ratings will be closely monitored.